ATE542542T1 - Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie - Google Patents

Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie

Info

Publication number: ATE542542T1
Authority: AT; Austria
Prior art keywords: diabetic neuropathy; activators; treat diabetic; treat; medicament
Prior art date: 2001-10-11

Application number

AT02774697T

Other languages

English (en)

Inventor

Michel Dreano

Pierre-Alain Vitte

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-11

Filing date

2002-10-10

Publication date

2012-02-15

2002-10-10 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542542T1 publication Critical patent/ATE542542T1/de

Links

208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
239000012190 activator Substances 0.000 title 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000011664 signaling Effects 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT02774697T 2001-10-11 2002-10-10 Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie ATE542542T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01123400		2001-10-11
PCT/EP2002/011364 WO2003033015A1 (en)	2001-10-11	2002-10-10	USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY

Publications (1)

Publication Number	Publication Date
ATE542542T1 true ATE542542T1 (de)	2012-02-15

Family

ID=8178778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02774697T ATE542542T1 (de)	2001-10-11	2002-10-10	Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie

Country Status (20)

Country	Link
US (3)	US7465441B2 (de)
EP (1)	EP1434597B1 (de)
JP (1)	JP2005505608A (de)
KR (1)	KR20050035151A (de)
CN (1)	CN1602203A (de)
AT (1)	ATE542542T1 (de)
AU (1)	AU2002340547B2 (de)
BR (1)	BR0213183A (de)
CA (1)	CA2463020A1 (de)
DK (1)	DK1434597T3 (de)
EA (1)	EA006881B1 (de)
ES (1)	ES2381341T3 (de)
HR (1)	HRP20040292A2 (de)
IL (1)	IL161310A0 (de)
MX (1)	MXPA04003442A (de)
NO (1)	NO20041908L (de)
PL (1)	PL369296A1 (de)
WO (1)	WO2003033015A1 (de)
YU (1)	YU29804A (de)
ZA (1)	ZA200402351B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU29804A (sh) *	2001-10-11	2006-08-17	Applied Research Systems Ars Holding N.V.	Upotreba aktivatora gp-130 u dijabetskoj neuropatiji
US20080076708A1 (en)	2003-05-13	2008-03-27	Valter Altarocca	Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
IL161672A0 (en)	2004-04-29	2004-09-27	Yeda Res & Dev	Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) *	2004-04-29	2004-09-27	Applied Research Systems	Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2011203356B2 (en) *	2004-04-29	2012-03-22	Yeda Research & Development Co., Ltd	IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
IL163856A0 (en) *	2004-09-01	2005-12-18	Applied Research Systems	Use of IL-6 in vascular complications
WO2008119110A1 (en) *	2007-03-30	2008-10-09	Baker Medical Research Institute	Treatment of obesity
DE102008057867A1 (de) *	2008-11-18	2010-05-20	B. Braun Melsungen Ag	Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN106924736B (zh) *	2017-05-09	2020-01-03	北京师范大学	gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用
FR3080533A1 (fr) *	2018-04-27	2019-11-01	Enterosys	Utilisation de l'il-6 pour le traitement du diabete
US20250281575A1 (en) *	2024-03-06	2025-09-11	Sonnet BioTherapeutics, Inc.	Methods for the treatment of diabetes-associated autonomic neuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849571A (en) *	1990-10-10	1998-12-15	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Latency active herpes virus promoters and their use
US5300292A (en) *	1991-05-03	1994-04-05	The Regents Of The University Of California	Composition and method for treating inflammation
IT1261787B (it)	1993-06-23	1996-06-03	Angeletti P Ist Richerche Bio	Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6479258B1 (en) *	1995-12-07	2002-11-12	Diversa Corporation	Non-stochastic generation of genetic vaccines
US5741772A (en) *	1997-02-03	1998-04-21	Amgen Inc.	Neurotrophic factor NNT-1
US7754855B1 (en)	1999-07-13	2010-07-13	Bolder Biotechnology, Inc.	Immunoglobulin fusion proteins
YU29804A (sh) *	2001-10-11	2006-08-17	Applied Research Systems Ars Holding N.V.	Upotreba aktivatora gp-130 u dijabetskoj neuropatiji

2002
- 2002-10-10 YU YU29804A patent/YU29804A/sh unknown
- 2002-10-10 EP EP02774697A patent/EP1434597B1/de not_active Expired - Lifetime
- 2002-10-10 CA CA002463020A patent/CA2463020A1/en not_active Abandoned
- 2002-10-10 KR KR1020047005334A patent/KR20050035151A/ko not_active Ceased
- 2002-10-10 PL PL02369296A patent/PL369296A1/xx not_active Application Discontinuation
- 2002-10-10 DK DK02774697.3T patent/DK1434597T3/da active
- 2002-10-10 AU AU2002340547A patent/AU2002340547B2/en not_active Ceased
- 2002-10-10 MX MXPA04003442A patent/MXPA04003442A/es unknown
- 2002-10-10 US US10/492,087 patent/US7465441B2/en not_active Expired - Lifetime
- 2002-10-10 ES ES02774697T patent/ES2381341T3/es not_active Expired - Lifetime
- 2002-10-10 HR HR20040292A patent/HRP20040292A2/hr not_active Application Discontinuation
- 2002-10-10 IL IL16131002A patent/IL161310A0/xx unknown
- 2002-10-10 AT AT02774697T patent/ATE542542T1/de active
- 2002-10-10 JP JP2003535817A patent/JP2005505608A/ja active Pending
- 2002-10-10 WO PCT/EP2002/011364 patent/WO2003033015A1/en not_active Ceased
- 2002-10-10 BR BR0213183-8A patent/BR0213183A/pt not_active IP Right Cessation
- 2002-10-10 CN CNA028247272A patent/CN1602203A/zh active Pending
- 2002-10-10 EA EA200400520A patent/EA006881B1/ru not_active IP Right Cessation
2004
- 2004-03-25 ZA ZA200402351A patent/ZA200402351B/en unknown
- 2004-05-10 NO NO20041908A patent/NO20041908L/no not_active Application Discontinuation
2008
- 2008-12-16 US US12/336,161 patent/US20090169506A1/en not_active Abandoned
2010
- 2010-04-05 US US12/754,335 patent/US8278286B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20040292A2 (en)	2005-06-30
AU2002340547B2 (en)	2008-04-03
US8278286B2 (en)	2012-10-02
PL369296A1 (en)	2005-04-18
US20090169506A1 (en)	2009-07-02
US7465441B2 (en)	2008-12-16
JP2005505608A (ja)	2005-02-24
NO20041908L (no)	2004-05-10
EA200400520A1 (ru)	2004-08-26
EP1434597A1 (de)	2004-07-07
BR0213183A (pt)	2004-08-31
ZA200402351B (en)	2005-03-29
ES2381341T3 (es)	2012-05-25
US20050058623A1 (en)	2005-03-17
KR20050035151A (ko)	2005-04-15
CA2463020A1 (en)	2003-04-24
YU29804A (sh)	2006-08-17
EP1434597B1 (de)	2012-01-25
EA006881B1 (ru)	2006-04-28
DK1434597T3 (da)	2012-02-27
US20100189684A1 (en)	2010-07-29
CN1602203A (zh)	2005-03-30
MXPA04003442A (es)	2004-07-08
IL161310A0 (en)	2004-09-27
WO2003033015A1 (en)	2003-04-24

Publication	Publication Date	Title
ATE555803T1 (de)	2012-05-15	Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60236413D1 (de)	2010-07-01	Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE542542T1 (de)	2012-02-15	Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie
ATE255894T1 (de)	2003-12-15	Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE438405T1 (de)	2009-08-15	Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
ATE447403T1 (de)	2009-11-15	Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
DE602005026276D1 (de)	2011-03-24	Myricitrin verbindungen zur behandlung von schlafstörungen
DE69918972D1 (de)	2004-09-02	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE309817T1 (de)	2005-12-15	Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE361071T1 (de)	2007-05-15	Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE359808T1 (de)	2007-05-15	Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE402694T1 (de)	2008-08-15	Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE60213365D1 (de)	2006-09-07	Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE536874T1 (de)	2011-12-15	Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60330233D1 (de)	2010-01-07	Arsentherapie zur behandlung von autoimmunerkrankungen
ATE374025T1 (de)	2007-10-15	Verbindungen zur beseitigung und/oder linderung der anhedonie
ATE314066T1 (de)	2006-01-15	Verwendung von buprenorphin zur therapie der harninkontinenz
ATE302009T1 (de)	2005-09-15	Ubichinon qn zur behandlung von migräneschmerzen
ATE288263T1 (de)	2005-02-15	Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE318594T1 (de)	2006-03-15	Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE69924385D1 (de)	2005-04-28	Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE275949T1 (de)	2004-10-15	Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
ATE286390T1 (de)	2005-01-15	Felabamat-derivate zur behandlung von neuropathischem schmerz
DE60111571D1 (de)	2005-07-21	Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
ATE427754T1 (de)	2009-04-15	Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen